Joseph Schwartz, an analyst from Leerink Partners, maintained the Hold rating on Sarepta Therapeutics. The associated price target was raised to $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Hold rating due to a combination of factors impacting Sarepta Therapeutics. The company’s recent financial results were in line with expectations, but there is uncertainty surrounding the demand for Elevidys, their treatment for Duchenne muscular dystrophy. Sales have declined, and the future demand is unclear due to recent controversies involving the FDA and safety concerns.
Additionally, the company’s limb-girdle muscular dystrophy program is on hold pending regulatory updates, and there are questions about the sustainability of their PMO franchise. The financial stability of Sarepta is also a concern, particularly their ability to manage debt obligations due in 2027 without refinancing. These factors contribute to the cautious outlook, leading to a Hold rating as the market awaits clearer demand trends and regulatory developments.
In another report released yesterday, TD Cowen also maintained a Hold rating on the stock with a $17.00 price target.